As we have previously reported, recent evidence suggests that incretin mimetic medications are linked to pancreatitis and pancreatic cancer. The American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications to make patient level data on their products available for an independent review. The ADA is concerned with the causal link between these medications, commonly sold as Byetta, Januvia/Janumet and Victoza, and pancreatitis and pancreatic cancer.

The ADA is calling all pharmaceutical companies with incretin therapies in development or currently marketed to make this patient-level data available.

If you or a loved one have suffered from pancreatitis or pancreatic cancer after taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.